欢迎进入 投资云南@云南招商网

州市招商

文山

项目查询

关键字:
所属行业:
投资金额:
- 万元
 
您现在的位置是: 首页--生物医药和大健康--详细
中成药加工建设项目Construction Project of Chinese Patent Medicine Processing
发布时间:2016-07-07 14:39:51   来源:本站   作者:   点击:465次

Name

中成药加工建设项目

Construction Project of Chinese Patent Medicine Processing

Industry Involved

Modern Bio-medicine

Site

Tianjing Block, Dali Innovative Industrial Park

Description

With the improvement of people's life quality and under the tendency of returning to nature and development of green and pure natural medicine, Chinese patent medicines benefiting the nation and the people and having strong development advantages shall be included into the scope of development. To meet the demands of domestic medicine market and further promote added value of the product, it is to build this project into an important production base of Yunnan Safflower - Chinese patent medicine in Yunnan Province by relying on Yunnan Safflower resources in Dali planting region and taking the demands of domestic and foreign markets as guide.

Content

Construction scale: This project is to produce such products as Yunnan Safflower Xanthein Injection with an annual output of 20 million bottles, Safflower Ruyi Pill with an annual output of 1 million boxes, and Safflower Xiaoyao Pill with an annual output of 1 million boxes by relying on 53,000 mu Yunnan Safflower in Dali Prefecture. Its total floor area is 60,500 m2.

Construction duration: 2 years

Land area: 61,000 m2

Supporting Conditions

Dali Prefecture, rich in biological resources and as one of main medicinal material production areas in Yunnan Province, is famous for many varieties and sound quality. There are over 600 Chinese herbal medicines that are state-operated. At present, Dali Prefecture has become the largest high-quality safflower production and planting base in Yunnan Province. Broad planting area creates advantaged resource superiority for production of Yunnan Safflower. Of them, the annual output of dry safflower and dry safflower seed is 1590t and 1190t respectively. In addition to rich Yunnan Safflower resources, this construction project of Bio-pharmaceutical Industrial Park in Dali Innovative Industrial Park also enjoys preferable conditions for construction. This park strongly supports the development of bio-pharmaceutical enterprises and has such bio-pharmaceutical enterprises as Yunnan Dali Tongda Biological Medicine Industry Co., Ltd., Dali Pharmaceutical Co., Ltd., and Yunnan Dali Ruihe Pharmaceutical Co., Ltd. settled herein. To promote the development of bio-medicine industry, this park is to actively introduce pharmaceutical enterprises with strong R&D strength and competitiveness.

Investment Estimate and Fund Raising

Total investment of this project is RMB 399,609,000 which is mainly from self-financing by enterprise, bank loan and other channels. Among them, the amount of self-raised fund and loan from financial institutions is RMB 149,609,000 and RMB 250 million respectively.

Preferential Policies Applicable

According to corresponding preferential tax policies for enterprises in national level development zones, related preferential policies on investment promotion are mainly reflected in those for high and new tech enterprises with domestic investment in national level hi-tech development zone, namely, corporate income tax is levied as per the tax rate of 15%. Newly-founded high-tech enterprises in national level hi-tech development zone are exempted from income tax for 2 years since the year starting business. Enterprises in national level hi-tech development zone are exempted from import tariff and import value-added tax in terms of new high-tech product development. Export products produced by high-tech enterprises are exempted from export tariff (except restrained products on export and unless otherwise stipulated by the nation).

Market Prediction (Analysis)

Recent years have seen steady growth in total industrial output value of Chinese patent medicines in China. In 2014, total industrial output value of our Chinese patent medicines was RMB 614.1 billion, accounting for 23.80% total industrial output value of our medical industry. Driven by increasingly extensive use of Chinese herbal pieces and continuous growth of traditional Chinese medicine industry, the industry of Chinese herbal pieces has strong growth momentum. With improvement in living standard, the health care product market of Chinese patent medicine will enter rapid growth period and the price of Chinese patent medicine materials will go up steadily. The demand on geo-authentic Chinese medicinal materials increases at an annual growth rate of 10%. This growth rate will be higher than the average. The prospect for entering international market is vast as long as green, pollution-free and high-quality products are produced as per GAP standards.

Profit Model and Preliminary Benefit Analysis

Economic benefit: After this project is put into production, the sales revenue of Yunnan Safflower products will reach RMB 433 million; the net profit will reach RMB 144,423,800; tax revenue will be RMB 54.36 million; the payback period is 4.5 years (including 2 years of construction period).

Social benefit: After this project is completed, it may directly promote the employment of 300 persons, increase rural income, drive the development of Yunnan Safflower industry in Dali Prefecture and elevate the level of green economy.

Risk Analysis

In this project, there may exist such three major types of risks as market risk, financial risk and management risk. The enterprises shall, under the guidance of diversified national economic policies and industrial policies, gather information, identify optimal solution and reasonably determine respective development objectives and strategies; enhance internal management, improve service and management level, reduce operating cost and maximize operating efficiency to build respective unique advantages and strengthen the capacity against policy risk.

Cooperation Pattern

Sole proprietorship, cooperation, joint venture and other patterns

Contact Information

Contact Unit: Investment Invitation and Cooperation Bureau, the Management Committee of Dali Innovative Industrial Park

Contact Person: Li Jun

Tel.: 0872-2317995

Fax: 0872-2310093

E-mail: lijunkorn@163.com


关于我们| 商会平台| 信息公开| 联系我们 滇ICP备08002862号

0871-67195654/67195610

电子邮件:yunnanzs@163.com

云南招商官方微信

法制在线官方微信

管理员登录      不良信息报警      云南网监      网站备案      平台入口      招商大数据平台项目查询系统